2005, Number 2
<< Back Next >>
Rev Mex Anest 2005; 28 (2)
Comparative evaluation of clinical conditions for the tracheal intubation obtained with two marks of vecuronium
Infante-Cosío G, López-Muñoz FJ, Guevara-López U, Lara-Solares A
Language: Spanish
References: 17
Page: 85-90
PDF size: 69.68 Kb.
ABSTRACT
An experimental study was carried out to compare the effectiveness and antinociceptive potential of parecoxib vs IV morphine in the PIFIR model. Experiments were carried out in female Wistar rats, using the PIFIR model. Under anesthesia, the caudal artery was canulated, uric acid was applied intraarticularly in the right hind leg, and electrodes were placed in both hind legs. Rats then walked on rotating cylinders, measuring contact of each leg with the cylinder during a two-minute span. Data were obtained every 30 minutes for 4 hours. These are expressed as functionality index (FI%), with zero meaning established arthritic pain. The study involved the administration of parecoxib or IV morphine, eight different doses, n = 6 for each dose, to a total 108 rats. Results showed a dose-dependent relation for both drugs. As for antinociceptive effectiveness, parecoxib was equivalent to morphine. Regarding the appearance of the effect in time, maximal effect began 0.5 h after administration; both parecoxib and morphine were comparable in terms of time until the effect and magnitude of antinociception. As for antinociceptive effectiveness, there were different “relative potencies”, depending on the comparison point. At DE
33, parecoxib was 3.7 times more potent than morphine. Under experimental conditions, parecoxib was as effective an analgesic as morphine, which demonstrates the analgesic usefulness of the former. The most important differences were in potency profiles, depending on the point of comparison for pharmacological potency.
REFERENCES
Domínguez, et al. Analgesic efficacy of the combination metamizol + morphine after subchronic treatment in rats. Drug Dev Res 2000;51:260-261.
Casy, et al. Opioid Analgesic: chemistry and receptors. Edited by Plenum Press, New York, 1986. Chap 2.
Christrup LL. Morphine metabolites. Acta Anaesthesiol Scand 1997;41:116-122.
Faura, et al. Lack of morphine-6-glucuronide antinociception after morphine treatment. Is morphine-3-glucuronide involved? Pain 1996;65:25-30.
Shung-Tai, et al. The magnitude of acute tolerance to morphine analgesia: Concentration-dependent or time-dependent? Anesth Analg 2002;95:948-51.
Hawkey CJ. COX-2. Lancet 1999;353:307-314.
Martínez, et al. Involvement of peripheral cyclooxigenase-1 and cyclooxigenase-2 in inflammatory pain; JPP 2002;54:405-412.
Cheer SM, Goa KL, Parecoxib (Parecoxib Sodium). Drugs 2001;61:1133-1141.
Randall, et al. Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects. Am J Gastroenterol 2002;97:65-71.
Desjardins, et al. The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperatively. Anesth-Analg 2001;93:721-7.
Noveck, et al. Parecoxib sodium does not impair platelet function in healthy elderly and non-elderly individuals. Clin Drug Invest 2001;21:465-476.
Vadillo, et al. Usefulness of the pain -induced functional impairment model to relate plasma levels of analgesics to their efficacy in rats. J Pharm Pharmacol 1995;47:462-465.
López-Muñoz FJ, et al. A new model to assess analgesic activity: Pain-induced functional impairment in the rat (PIFIR). Drug Dev Res 1993;28:169-175.
Lopez-Muñoz, et al. Analgesic effects of combinations containing opioid drugs with either aspirin or acetaminophen in the rat. Drug Dev Res 1993;29:299-304.
Porter J, Hick H. Addiction rare in patients treated with narcotics (letter). N Engl J Med 1980;302:123.
Aziz K, et al. A pharmacokinetic study of intramuscular (IM) parecoxib sodium in normal subjects. J Clin Pharmacol 2001;41: 1111-1119.
Douglas O, Keri W, Wagstaff AJ. Valdecoxib. Drugs 2002;62: 2059-2071.
Full text